Amgen and Zai Lab's Phase III trial, FORTITUDE-101, showed that bemarituzumab with mFOLFOX6 improved overall survival in patients with unresectable gastric cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Amgen and Zai Lab's Phase III trial, FORTITUDE-101, showed that bemarituzumab with mFOLFOX6 improved overall survival in patients with unresectable gastric cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing